Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study

Christina M. Schilder,Petronella C. Eggens,Caroline Seynaeve,Sabine C. Linn,Willem Boogerd,Chad M. Gundy,Louk V. Beex,Frits S. Van Dam,Sanne B. Schagen
DOI: https://doi.org/10.1080/02841860802314738
IF: 4.311
2009-01-01
Acta Oncologica
Abstract:BACKGROUND: Previous studies have indicated that a subset of cancer patients treated with chemotherapy show cognitive deficits and/or experience cognitive complaints, whereas literature about the influence of hormonal therapies on cognition is sparse. Because of the accumulating knowledge about the importance of estrogen for cognitive functioning, there is growing concern about adjuvant hormonal therapy for breast cancer (BC) affecting cognition. We examined the cognitive functioning of postmenopausal BC patients who were, following doxorubicin/cyclophosphamide (AC) chemotherapy, randomized to tamoxifen or exemestane, and compared their performance with that of non-cancer controls.MATERIALS AND METHODS: Thirty BC patients using tamoxifen and 50 patients using exemestane underwent interviews, questionnaires and cognitive tests, on average two years after completion of AC chemotherapy. Forty eight healthy controls were tested with similar measures.RESULTS: Memory complaints were reported by 28% of AC/tamoxifen users, 24% of AC/exemestane users and 6% of healthy controls (p=0.02). Cognitive testing revealed no statistically significant differences between tamoxifen and exemestane users, but suggested that tamoxifen use is possibly related to worse verbal functioning, while exemestane use is possibly related to slower manual motor speed. Both patient groups performed significantly worse than healthy controls on verbal fluency and information processing speed.DISCUSSION: Our findings show that sequential treatment of AC-chemotherapy and hormonal therapy in postmenopausal, primary BC is associated with lower test scores for certain cognitive functions, and provide indications for possibly distinctive associations for different types of hormonal treatment. Future research with larger groups is recommended to obtain a more definite picture.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to evaluate the cognitive functions of post - menopausal breast cancer patients (using tamoxifen and exemestane respectively) who received different hormonal therapies after adjuvant chemotherapy, and compare them with a non - cancer control group. Specifically, the research objectives are as follows: 1. **Research differences**: To explore whether there are differences in the cognitive functions of post - menopausal breast cancer patients randomly assigned to tamoxifen or exemestane treatment after completing doxorubicin/cyclophosphamide (AC) chemotherapy. 2. **Compare cognitive functions**: To compare the cognitive functions of post - menopausal breast cancer patients who received hormonal therapy following AC chemotherapy with a healthy control group of the same age group. ### Research background Previous studies have shown that some cancer patients who received chemotherapy exhibited cognitive impairment or reported cognitive problems, while there were fewer studies on the impact of hormonal therapy on cognition. Since the importance of estrogen for cognitive function has been gradually recognized, people have begun to pay attention to whether adjuvant hormonal therapy will affect the cognitive function of breast cancer patients. Therefore, this study aims to evaluate the impact of two commonly - used hormonal therapy drugs (tamoxifen and exemestane) on patients' cognitive functions through detailed neuropsychological tests and compare them with a healthy control group. ### Methods - **Participants**: The study included three groups of people: 30 patients using tamoxifen, 50 patients using exemestane, and 48 members of the healthy control group. - **Testing methods**: Participants received detailed cognitive tests, including evaluations of multiple aspects such as memory, attention, language, and executive function. - **Statistical analysis**: Multivariate analysis of variance (MANOVA) and univariate analysis of variance (ANOVA) were used to compare the differences in cognitive functions among the groups, and factors such as age, IQ, and the time of chemotherapy completion were adjusted. ### Main findings - **Self - reported cognitive problems**: The proportion of patients reporting memory problems in the patient group was significantly higher than that in the healthy control group (25% vs 6%), but there was no significant difference between tamoxifen and exemestane users. - **Cognitive test performance**: Overall, there was no significant difference in cognitive functions between tamoxifen and exemestane users. However, compared with the healthy control group, the patient group performed worse in verbal fluency and information processing speed. - **Health - related quality of life**: The patient group reported more fatigue and sleep disorders, while there was no significant difference in anxiety and depressive symptoms among the three groups. - **Menopausal symptoms**: The patient group reported more menopausal symptoms, especially hot flushes, cold sweats, and night sweats. ### Conclusion This study found that post - menopausal breast cancer patients had lower test scores in some cognitive functions during the process of receiving hormonal therapy (tamoxifen or exemestane) following AC chemotherapy. This indicates that adjuvant chemotherapy and hormonal therapy may have a certain negative impact on cognitive function, but the specific mechanism still needs further study. In addition, the impact of different types of hormonal therapy on cognitive function may be different, and studies with a larger sample size are needed to verify these preliminary findings.